Grozav Adrian G, Chikamori Kenichi, Kozuki Toshiyuki, Grabowski Dale R, Bukowski Ronald M, Willard Belinda, Kinter Michael, Andersen Anni H, Ganapathi Ram, Ganapathi Mahrukh K
Clinical Pharmacology Program, Taussig Cancer Institute, Cleveland, OH 44195, USA.
Nucleic Acids Res. 2009 Feb;37(2):382-92. doi: 10.1093/nar/gkn934. Epub 2008 Nov 29.
We previously reported that phosphorylation of topoisomerase (topo) IIalpha at serine-1106 (Ser-1106) regulates enzyme activity and sensitivity to topo II-targeted drugs. In this study we demonstrate that phosphorylation of Ser-1106, which is flanked by acidic amino acids, is regulated in vivo by casein kinase (CK) Idelta and/or CKIepsilon, but not by CKII. The CKI inhibitors, CKI-7 and IC261, reduced Ser-1106 phosphorylation and decreased formation of etoposide-stabilized topo II-DNA cleavable complex. In contrast, the CKII inhibitor, 5,6-dichlorobenzimidazole riboside, did not affect etoposide-stabilized topo II-DNA cleavable complex formation. Since, IC261 specifically targets the Ca(2+)-regulated isozymes, CKIdelta and CKIepsilon, we examined the effect of down-regulating these enzymes on Ser-1106 phosphorylation. Down-regulation of these isozymes with targeted si-RNAs led to hypophosphorylation of the Ser-1106 containing peptide. However, si-RNA-mediated down-regulation of CKIIalpha and alpha' did not alter Ser-1106 phosphorylation. Furthermore, reduced phosphorylation of Ser-1106, observed in HRR25 (CKIdelta/epsilon homologous gene)-deleted Saccharomyces cerevisiae cells transformed with human topo IIalpha, was enhanced following expression of human CKIepsilon. Down-regulation of CKIdelta and CKIepsilon also led to reduced formation of etoposide stabilized topo II-DNA cleavable complex. These results provide strong support for an essential role of CKIdelta/epsilon in phosphorylating Ser-1106 in human topo IIalpha and in regulating enzyme function.
我们之前报道过,拓扑异构酶(topo)IIα在丝氨酸1106(Ser-1106)位点的磷酸化调节酶活性以及对topo II靶向药物的敏感性。在本研究中,我们证明,位于酸性氨基酸两侧的Ser-1106的磷酸化在体内受酪蛋白激酶(CK)Idelta和/或CKIepsilon调节,而非受CKII调节。CKI抑制剂CKI-7和IC261可降低Ser-1106的磷酸化,并减少依托泊苷稳定的topo II-DNA可切割复合物的形成。相反,CKII抑制剂5,6-二氯苯并咪唑核糖核苷不影响依托泊苷稳定的topo II-DNA可切割复合物的形成。由于IC261特异性靶向Ca(2+)调节的同工酶CKIdelta和CKIepsilon,我们研究了下调这些酶对Ser-1106磷酸化的影响。用靶向si-RNA下调这些同工酶导致含Ser-1106肽段的低磷酸化。然而,si-RNA介导的CKIIα和α'下调并未改变Ser-1106的磷酸化。此外,在用人类topo IIα转化的HRR25(CKIdelta/epsilon同源基因)缺失的酿酒酵母细胞中观察到的Ser-1106磷酸化降低,在人类CKIepsilon表达后增强。CKIdelta和CKIepsilon的下调也导致依托泊苷稳定的topo II-DNA可切割复合物的形成减少。这些结果为CKIdelta/epsilon在人类topo IIα中Ser-1106磷酸化及调节酶功能方面的重要作用提供了有力支持。